RxDoctor Payments Data

Heather Harris

Adult Health · Baton Rouge, LANPI 1619155686

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.4% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,149, 2.2 times the $530 reported in 2021.

$3,615in general payments, 2019–2025

Across 185 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$658
  • Johnson & Johnson$553
  • Madrigal Pharmaceuticals$432
  • Gilead$379
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$300
  • Intercept Pharmaceuticals, Inc.$208
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,48396%
  • Education$1324%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,615 in reported general payments places this provider in the 70th percentile of 203 adult health providers in Louisiana.

See all adult health providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid12$88,215
LinzessLinaclotide120$82,725
XifaxanRifaximin14$49,355
CreonLipase/Protease/Amylase15$44,219
VemlidyTenofovir Alafenamide13$21,034
MotegrityPrucalopride Succinate17$9,483
Sucralfate50$7,521
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates108$6,796
Ursodiol32$4,553
Colestipol Hcl28$3,585
Mesalamine11$2,568
ClenpiqSod Picosulf/Mag Ox/Citric Ac14$2,378
Lubiprostone26$1,589
Pantoprazole Sodium180$1,038
Omeprazole76$971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$658$126,944135 claims
Intercept Pharmaceuticals, Inc.Ocaliva$208$88,21512 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$300$49,35514 claims
GileadVemlidy$379$21,03413 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$122$9,48317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 203 adult health providers in Louisiana.

Other adult health in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →